Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-2 receptor alpha chain (IL2RA), also known as CD25, is a type I transmembrane protein that binds interleukin-2 (IL-2). It is essential for the high-affinity binding of IL-2, a cytokine critical for T cell proliferation, survival, differentiation, and immune regulation. While the alpha chain binds IL-2 with low affinity on its own, it forms a high-affinity heterotrimeric complex with the beta and gamma chains, enabling potent cellular responses. CD25 is expressed on activated T cells, regulatory T cells (Tregs), activated B cells, and natural killer (NK) cells, with expression upregulated upon immune activation. A soluble form of CD25 exists and serves as a biomarker for immune activation. Targeting CD25 is being explored for therapeutic purposes, such as expanding regulatory T cells in autoimmunity.
Agonist to stimulate downstream signaling through the IL-2 receptor complex; antagonists or antibodies to block IL-2 binding and subsequent signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 2 Receptor Alpha Chain (IL2RA).